 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
21 March 2006 | Volume 144 Issue 6 | Pages 415-420
Background: Telithromycin is a ketolide antibiotic approved by the U.S. Food and Drug Administration for acute bacterial infections causing sinusitis, bronchitis, and community-acquired pneumonia.
Objective: To describe 3 cases of severe hepatotoxicity in patients receiving telithromycin.
Design: Case reports.
Setting: A tertiary care medical center.
Patients: 3 previously healthy patients who had recently taken telithromycin and took no other prescription medications.
Measurements: Serologic, histologic, and liver function tests.
Results: Within a few days of receiving telithromycin, the patients presented with acute hepatitis. All had jaundice and markedly abnormal results on liver function tests. Results of viral serologic tests were negative. One patient spontaneously recovered, 1 required orthotopic liver transplantation, and 1 died. Histologic examination in the latter 2 patients showed massive hepatic necrosis.
Limitations: Two patients had some history of alcohol use. The frequency of severe telithromycin-related hepatotoxicity cannot be established with case reports.
Conclusions: Telithromycin can cause severe hepatotoxicity. Caution is advised in prescribing this drug pending additional postmarketing surveillance data.
Editors' Notes
Context
Contribution
Cautions
Implications
—The Editors
Author and Article Information
From Carolinas Medical Center, Charlotte Gastroenterology and Hepatology, Carolinas HealthCare System, and Carolinas Pathology Group, Charlotte, North Carolina.
Grant Support: None.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Kimberly D. Clay, MD, Carolinas Medical Center, 1000 Blythe Boulevard, Charlotte, NC 28203; e-mail, kimberly.clay{at}carolinashealthcare.org.
Current Author Addresses: Drs. Clay, Pope, Rissmiller, Purdum, and Banks: Carolinas Medical Center, 1000 Blythe Boulevard, Charlotte, NC 28203.
Dr. Hanson: Charlotte Gastroenterology and Hepatology, 2015 Randolph Road 208, Charlotte, NC 28207.
Author Contributions: Conception and design: K.D. Clay, J.S. Hanson, S.D. Pope, R.W. Rissmiller.
Analysis and interpretation of the data: K.D. Clay, S.D. Pope, R.W. Rissmiller, P.P. Purdum.
Drafting of the article: K.D. Clay, J.S. Hanson, S.D. Pope, R.W. Rissmiller, P.P. Purdum, P.M. Banks.
Critical revision of the article for important intellectual content: K.D. Clay, J.S. Hanson, S.D. Pope, R.W. Rissmiller, P.P. Purdum.
Final approval of the article: K.D. Clay, J.S. Hanson, R.W. Rissmiller, P.P. Purdum.
Provision of study materials or patients: K.D. Clay, J.S. Hanson, R.W. Rissmiller, P.M. Banks.
Administrative, technical, or logistic support: K.D. Clay, S.D. Pope.
Collection and assembly of data: K.D. Clay, S.D. Pope. ARTICLE
Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. Bolesta and B. P. Roslund Elevated hepatic transaminases associated with telithromycin therapy: A case report and literature review Am. J. Health Syst. Pharm., January 1, 2008; 65(1): 37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-M. Kim, K. D. Yu, J. H. Lee, H. K. Kim, and S.-H. Lee Controlled Trial of a 5-Day Course of Telithromycin versus Doxycycline for Treatment of Mild to Moderate Scrub Typhus Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2011 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Ross The FDA and the Case of Ketek N. Engl. J. Med., April 19, 2007; 356(16): 1601 - 1604. [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Bedard and M. Gilbert Telithromycin-Induced TEN: Report of a Case Arch Dermatol, March 1, 2007; 143(3): 427 - 428. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz Projecting future drug expenditures--2007 Am. J. Health Syst. Pharm., February 1, 2007; 64(3): 298 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Bertino Severe hepatotoxicity of telithromycin. Ann Intern Med, September 19, 2006; 145(6): 472 - 472. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tonks What's new in the other general journals. BMJ, April 1, 2006; 332(7544): 781 - 782. [Full Text] [PDF]
|
|
|
|
|
|
M. Turner, G. R. Corey, and E. Abrutyn Telithromycin. Ann Intern Med, March 21, 2006; 144(6): 447 - 448. [Full Text] [PDF]
|
|
Read all Rapid Responses
Article
